Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats

Yoshiyuki Ohno, Yasuhiko Yamada, Takashi Usui, Koichiro Takahashi, Fumito Tsuchiya, Hisakazu Ohtani, Hitoshi Sato, Yasufumi Sawada, Tatsuji Iga

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Incadronate concentrates into the bone as a target organ after intravenous administration of incadronate disodium. Mature osteoclasts has take up incadronate from the bone surface and convert it from an active to an inactive form. As a result, incadronate decreases the plasma calcium concentration by suppressing bone resorption. In this study, the pharmacokinetic and pharmacodynamic (PK/PD) analysis model for ascertaining the anti-hypercalcemic effects of incadronate disodium was developed in rats. Data on both the concentration of incadronate in bone and that of free calcium in blood after intravenous administration from our previous study were used for analysis. To estimate the concentration in the surface layer of bone, data on the concentration of incadronate in bone after single intravenous administration were analyzed based on the PK model considering three-compartments. The estimated concentrations in the surface layer in bone were applied to the PD model as an input function. The PD model was developed to analyze the changes in the plasma calcium concentration after a single intravenous administration considering an irreversible inhibition of osteoclast activity. The obtained fitted curves were in good agreement with the observed data. The model could explain the long duration of the antihypercalcemic effect of incadronate disodium and should be useful for planning rational dose regimens for effective antihypercalcemic therapy.

Original languageEnglish
Pages (from-to)1290-1293
Number of pages4
JournalBiological and Pharmaceutical Bulletin
Volume24
Issue number11
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Pharmacokinetics
Bone and Bones
Intravenous Administration
Osteoclasts
Calcium
cimadronate
Bone Resorption

Keywords

  • Antihypercalcemic effect
  • Incadronate
  • Osteoclast
  • Pharmacodynamic
  • Pharmacokinetic
  • PK/PD model

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats. / Ohno, Yoshiyuki; Yamada, Yasuhiko; Usui, Takashi; Takahashi, Koichiro; Tsuchiya, Fumito; Ohtani, Hisakazu; Sato, Hitoshi; Sawada, Yasufumi; Iga, Tatsuji.

In: Biological and Pharmaceutical Bulletin, Vol. 24, No. 11, 2001, p. 1290-1293.

Research output: Contribution to journalArticle

Ohno, Y, Yamada, Y, Usui, T, Takahashi, K, Tsuchiya, F, Ohtani, H, Sato, H, Sawada, Y & Iga, T 2001, 'Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats', Biological and Pharmaceutical Bulletin, vol. 24, no. 11, pp. 1290-1293. https://doi.org/10.1248/bpb.24.1290
Ohno, Yoshiyuki ; Yamada, Yasuhiko ; Usui, Takashi ; Takahashi, Koichiro ; Tsuchiya, Fumito ; Ohtani, Hisakazu ; Sato, Hitoshi ; Sawada, Yasufumi ; Iga, Tatsuji. / Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats. In: Biological and Pharmaceutical Bulletin. 2001 ; Vol. 24, No. 11. pp. 1290-1293.
@article{1912c047585f44cbba2ce4a756543f88,
title = "Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats",
abstract = "Incadronate concentrates into the bone as a target organ after intravenous administration of incadronate disodium. Mature osteoclasts has take up incadronate from the bone surface and convert it from an active to an inactive form. As a result, incadronate decreases the plasma calcium concentration by suppressing bone resorption. In this study, the pharmacokinetic and pharmacodynamic (PK/PD) analysis model for ascertaining the anti-hypercalcemic effects of incadronate disodium was developed in rats. Data on both the concentration of incadronate in bone and that of free calcium in blood after intravenous administration from our previous study were used for analysis. To estimate the concentration in the surface layer of bone, data on the concentration of incadronate in bone after single intravenous administration were analyzed based on the PK model considering three-compartments. The estimated concentrations in the surface layer in bone were applied to the PD model as an input function. The PD model was developed to analyze the changes in the plasma calcium concentration after a single intravenous administration considering an irreversible inhibition of osteoclast activity. The obtained fitted curves were in good agreement with the observed data. The model could explain the long duration of the antihypercalcemic effect of incadronate disodium and should be useful for planning rational dose regimens for effective antihypercalcemic therapy.",
keywords = "Antihypercalcemic effect, Incadronate, Osteoclast, Pharmacodynamic, Pharmacokinetic, PK/PD model",
author = "Yoshiyuki Ohno and Yasuhiko Yamada and Takashi Usui and Koichiro Takahashi and Fumito Tsuchiya and Hisakazu Ohtani and Hitoshi Sato and Yasufumi Sawada and Tatsuji Iga",
year = "2001",
doi = "10.1248/bpb.24.1290",
language = "English",
volume = "24",
pages = "1290--1293",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats

AU - Ohno, Yoshiyuki

AU - Yamada, Yasuhiko

AU - Usui, Takashi

AU - Takahashi, Koichiro

AU - Tsuchiya, Fumito

AU - Ohtani, Hisakazu

AU - Sato, Hitoshi

AU - Sawada, Yasufumi

AU - Iga, Tatsuji

PY - 2001

Y1 - 2001

N2 - Incadronate concentrates into the bone as a target organ after intravenous administration of incadronate disodium. Mature osteoclasts has take up incadronate from the bone surface and convert it from an active to an inactive form. As a result, incadronate decreases the plasma calcium concentration by suppressing bone resorption. In this study, the pharmacokinetic and pharmacodynamic (PK/PD) analysis model for ascertaining the anti-hypercalcemic effects of incadronate disodium was developed in rats. Data on both the concentration of incadronate in bone and that of free calcium in blood after intravenous administration from our previous study were used for analysis. To estimate the concentration in the surface layer of bone, data on the concentration of incadronate in bone after single intravenous administration were analyzed based on the PK model considering three-compartments. The estimated concentrations in the surface layer in bone were applied to the PD model as an input function. The PD model was developed to analyze the changes in the plasma calcium concentration after a single intravenous administration considering an irreversible inhibition of osteoclast activity. The obtained fitted curves were in good agreement with the observed data. The model could explain the long duration of the antihypercalcemic effect of incadronate disodium and should be useful for planning rational dose regimens for effective antihypercalcemic therapy.

AB - Incadronate concentrates into the bone as a target organ after intravenous administration of incadronate disodium. Mature osteoclasts has take up incadronate from the bone surface and convert it from an active to an inactive form. As a result, incadronate decreases the plasma calcium concentration by suppressing bone resorption. In this study, the pharmacokinetic and pharmacodynamic (PK/PD) analysis model for ascertaining the anti-hypercalcemic effects of incadronate disodium was developed in rats. Data on both the concentration of incadronate in bone and that of free calcium in blood after intravenous administration from our previous study were used for analysis. To estimate the concentration in the surface layer of bone, data on the concentration of incadronate in bone after single intravenous administration were analyzed based on the PK model considering three-compartments. The estimated concentrations in the surface layer in bone were applied to the PD model as an input function. The PD model was developed to analyze the changes in the plasma calcium concentration after a single intravenous administration considering an irreversible inhibition of osteoclast activity. The obtained fitted curves were in good agreement with the observed data. The model could explain the long duration of the antihypercalcemic effect of incadronate disodium and should be useful for planning rational dose regimens for effective antihypercalcemic therapy.

KW - Antihypercalcemic effect

KW - Incadronate

KW - Osteoclast

KW - Pharmacodynamic

KW - Pharmacokinetic

KW - PK/PD model

UR - http://www.scopus.com/inward/record.url?scp=0035167936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035167936&partnerID=8YFLogxK

U2 - 10.1248/bpb.24.1290

DO - 10.1248/bpb.24.1290

M3 - Article

C2 - 11725966

AN - SCOPUS:0035167936

VL - 24

SP - 1290

EP - 1293

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 11

ER -